Switching to Tirzepatide: Liver Fibrosis

A new secondary analysis out of Hokkaido, Japan, adds a data point to a question clinicians keep asking: does switching a patient with type 2 diabetes from an existing GLP-1 receptor agonist to tirzepatide do anything for their liver? The Hokkaido-TZP study, published in the Journal of Diabetes and Its Complications on 14 August 2026, followed 182 patients with type 2 diabetes who switched to tirzepatide and were also at elevated risk of metabolic dysfunction-associated steatotic liver disease (MASLD)^[1]. The headline result: patients who started with the highest risk of liver scarring saw a statistically significant improvement in a fibrosis marker within six months, and that improvement did not track with how much weight they lost.

What MASLD is, and why type 2 diabetes raises the stakes

MASLD describes fat building up in the liver in someone who also has a cardiometabolic risk factor, such as type 2 diabetes, excess weight, high blood pressure, or abnormal cholesterol. A 2023 multisociety consensus process renamed the older terms NAFLD and NASH to MASLD and MASH (the inflamed form of the disease), partly because clinicians and patients found the older wording, built around "fatty" and "nonalcoholic", stigmatising and unhelpful^[2]. Type 2 diabetes is one of the strongest drivers of MASLD progressing toward fibrosis, the scarring that, over years, can advance toward cirrhosis. It is also a well-documented risk factor discussed on our semaglutide page and elsewhere in our GLP-1 coverage. That is the population the Hokkaido-TZP researchers set out to study.

A retrospective look at a real-world switch

This was a multicenter, retrospective study, meaning the researchers looked backward through existing patient records rather than enrolling people into a new trial from scratch. It is a secondary analysis of the larger Hokkaido-TZP study, focused on the subset of 182 patients who were already at high risk of MASLD when they switched from a GLP-1 receptor agonist to tirzepatide^[1]. The researchers tracked hepatic (liver) markers over six months and split patients into a low-risk and a high-risk group based on how much fibrosis risk they had at the start.

Two blood-test scores, not a biopsy

The study leaned on two noninvasive scores rather than liver biopsy, the traditional but invasive gold standard for staging liver disease. The Fibrosis-4 (FIB-4) index combines a patient's age with two liver enzymes, AST and ALT, and their platelet count into a single number that flags the likelihood of advanced scarring^[3]. The Hepatic Steatosis Index (HSI) uses the ratio of those same two liver enzymes plus body mass index, sex, and diabetes status to flag fatty liver itself, rather than scarring^[4]. Both were developed and validated as screening tools that let clinicians avoid an unnecessary biopsy in most patients, not as a replacement for one in someone who already needs a definitive diagnosis.

What changed after the switch

Across the full 182-patient group, switching to tirzepatide was associated with reductions in HbA1c (a measure of average blood sugar), body weight, and liver enzymes^[1]. The Hepatic Steatosis Index dropped in both the low-risk and high-risk groups, consistent with less fat accumulation in the liver. The more specific result is in the FIB-4 index: a statistically significant reduction appeared only in the high-risk group (P < 0.001), the patients who had the most scarring risk to begin with^[1]. The researchers also found that a higher baseline HSI predicted a bigger drop in FIB-4 after the switch, a modest but real correlation (Spearman's rho = 0.234, P = 0.005), meaning patients with more fat in the liver at the start tended to see the larger fibrosis-marker improvement^[1].

One finding argues against the easiest explanation. The authors report that improvements in these hepatic indices were not correlated with changes in body mass index or HbA1c^[1]. In other words, the liver benefit was not simply a byproduct of patients losing more weight or controlling their blood sugar better on tirzepatide than they had on their prior GLP-1 receptor agonist, such as semaglutide, liraglutide, or dulaglutide. Something in the switch appears to move the liver markers on its own track, and the study does not tell us what that mechanism is.

What this study doesn't show

This is a retrospective secondary analysis, not a randomised trial. There was no comparison group of similar patients who stayed on their original GLP-1 receptor agonist over the same six months, so it is not possible to say how much of the improvement would have happened anyway. FIB-4 and HSI are blood-test estimates, not biopsy-confirmed diagnoses; both carry real error margins and can be pulled around by things unrelated to liver fibrosis, such as acute illness affecting liver enzymes. The cohort is 182 patients from clinics across one Japanese region, followed for six months, which limits how confidently the finding generalises to other populations or to longer time horizons. Whether the FIB-4 improvement holds up, or eventually shows up in harder outcomes like biopsy-confirmed fibrosis stage or cirrhosis risk, is not something a six-month, non-biopsy study can answer.

It is also worth naming a disclosed conflict of interest plainly: two of the study's authors reported honoraria or research support from pharmaceutical companies, including Eli Lilly Japan, which markets tirzepatide as Mounjaro in Japan. That does not make the finding wrong, and journal-disclosed conflicts of interest are standard practice, but it is context worth weighing alongside the result.

Where this leaves patients and clinicians

If you have type 2 diabetes, are on a GLP-1 receptor agonist, and have been flagged for MASLD risk, this study is a reasonable conversation starter with your prescriber, not a reason to request a switch on your own. The available evidence suggests a liver-marker benefit to switching to tirzepatide in high-risk patients, but it comes from a single retrospective analysis without a control arm or biopsy confirmation. Whether that benefit is durable, whether it applies outside this cohort, and how it should weigh against other factors in choosing a diabetes medication are all questions for a clinician who knows your history and your labs.

Medical disclaimer: This article is for educational and journalistic purposes only and does not constitute medical advice. Peptides discussed may be classified as prescription medicines depending on your jurisdiction. Always consult a qualified healthcare professional before starting, stopping, or switching any medication. PeptideMethods.com does not sell, distribute, or facilitate the sale of any peptide product.